Evaluating the Pharmacokinetics of 400 mg Oral Dose of Raltegravir in HIV-Infected Pre-Menopausal Women

Inclusion Criteria: * HIV-1 infection documented by HIV serology or detectable viral load * Able to provide informed consent * In the opinion of the investigator, able to comply with their treatment regimen and study procedures * Currently receiving raltegravir as treatment for HIV infection. Subjects must have been on raltegravir for at least 3 weeks prior to the inpatient pharmacokinetic sampling stay. * All women of reproductive potential (who have not reached menopause or undergone bilateral oophorectomy, or tubal ligation) must have a negative serum β-HCG pregnancy test performed at screening. * Subjects must test negative for sexually transmitted infections (gonorrhea, chlamydia, trichomonas, bacterial vaginosis, or syphilis) at screening * All study volunteers must agree not to participate in a conception process (e.g., active attempt to become pregnant). * Subjects must be willing to abstain from intercourse, and vaginal instrumentation, including douching, within the 48 hours prior to all study visits. * If participating in sexual activity that could lead to pregnancy between study visits, the female study volunteer/male partner must use at least one reliable method of contraception (e.g., condoms, with or without a spermicidal agent; a diaphragm or cervical cap with spermicide; an IUD) Exclusion Criteria: * Pregnancy * Breastfeeding * Any condition which in the opinion of the investigator is likely to interfere with follow-up or ability to take the study medication appropriately * A positive test for bacterial vaginosis, syphilis, gonorrhea, chlamydia, or trichomonas